Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 1998 Apr 7

PMID 10180747

Citations 4

Authors

J A Johnson

E Friesen

Affiliations

Soon will be listed here.

Citing Articles

A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt.

Farid S, Elmahdawy M, Baines D Clin Drug Investig. 2018; 39(2):157-168.

PMID: 30460486 DOI: 10.1007/s40261-018-0730-5.

Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Daniel Mullins C, Wang J Pharmacoeconomics. 2002; 20(1):9-21.

PMID: 11817989 DOI: 10.2165/00019053-200220010-00002.

Reconciling decision models with the real world. An application to anaemia of renal failure.

Shih Y, Kauf T Pharmacoeconomics. 1999; 15(5):481-93.

PMID: 10537965 DOI: 10.2165/00019053-199915050-00006.

The effect of managed care on prescription drug costs and benefits.

Lyles A, Palumbo F Pharmacoeconomics. 1999; 15(2):129-40.

PMID: 10351187 DOI: 10.2165/00019053-199915020-00002.

References

Hadorn D, Baker D, Hodges J, Hicks N . Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996; 49(7):749-54. DOI: 10.1016/0895-4356(96)00019-4. View

Schroeder S, Cantor J . On squeezing balloons. Cost control fails again. N Engl J Med. 1991; 325(15):1099-100. DOI: 10.1056/NEJM199110103251510. View

Soumerai S, McLaughlin T, Ross-Degnan D, Casteris C, Bollini P . Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994; 331(10):650-5. DOI: 10.1056/NEJM199409083311006. View

Lipsy R . Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics. 1992; 1(4):265-81. DOI: 10.2165/00019053-199201040-00004. View

OBrien B, Drummond M, Labelle R, Willan A . In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994; 32(2):150-63. DOI: 10.1097/00005650-199402000-00006. View

Menon D, Schubert F, Torrance G . Canada's new guidelines for the economic evaluation of pharmaceuticals. Med Care. 1996; 34(12 Suppl):DS77-86. View

OBRIEN B . Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?. Med Care. 1996; 34(12 Suppl):DS99-108. View

Soumerai S, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I . Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991; 325(15):1072-7. DOI: 10.1056/NEJM199110103251505. View

. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. Int J Technol Assess Health Care. 1995; 11(4):796-7. DOI: 10.1017/s0266462300009247. View

10.

Briggs A, Sculpher M . Sensitivity analysis in economic evaluation: a review of published studies. Health Econ. 1995; 4(5):355-71. DOI: 10.1002/hec.4730040502. View

11.

Guyatt G, Sackett D, Sinclair J, Hayward R, Cook D, Cook R . Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA. 1995; 274(22):1800-4. DOI: 10.1001/jama.274.22.1800. View

12.

Soumerai S, Ross-Degnan D, Gortmaker S, Avorn J . Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment. JAMA. 1990; 263(6):831-9. View

13.

Hochla P, TUASON V . Pharmacy and Therapeutics committee. Cost-containment considerations. Arch Intern Med. 1992; 152(9):1773-5. View

14.

Armstrong E, Langley P . Disease management programs. Am J Health Syst Pharm. 1996; 53(1):53-8. DOI: 10.1093/ajhp/53.1.53. View

15.

Johnson J, Bootman J . Pharmacoeconomic analysis in formulary decisions: an international perspective. Am J Hosp Pharm. 1994; 51(20):2593-8. View

16.

Cooke J . The practical impact of pharmacoeconomics on institutional managers. Pharmacoeconomics. 1994; 6(4):289-97. DOI: 10.2165/00019053-199406040-00002. View

17.

Nash D, Catalano M, Wordell C . The formulary decision-making process in a US academic medical centre. Pharmacoeconomics. 1992; 3(1):22-35. DOI: 10.2165/00019053-199303010-00004. View

18.

Mason J . The generalisability of pharmacoeconomic studies. Pharmacoeconomics. 1997; 11(6):503-14. DOI: 10.2165/00019053-199711060-00001. View

19.

Macpherson P . The FDA just says yes. Hosp Health Netw. 1996; 70(10):34-6, 38. View